The downgrade from Buy to Neutral by Citigroup indicates a less optimistic outlook for PTC Therapeutics. The significant reduction in price target from $55 to $29 suggests that the analyst sees less upside potential in the stock, which could negatively impact investor sentiment and put downward pressure on the stock price in the short term.